Neuronal autophagy is essential for neuronal survival and the maintenance of neuronal homeostasis. Increasing evidence has implicated autophagic dysfunction in the pathogenesis of Alzheimer's disease (AD). The mechanisms underlying autophagic failure in AD involve several steps, from autophagosome formation to degradation. The effect of modulating autophagy is context-dependent. Stimulation of autophagy is not always beneficial. During the implementation of therapies that modulate autophagy, the nature of the autophagic defect, the timing of intervention, and the optimal level and duration of modulation should be fully considered.
Introduction
The term "autophagy" refers to a catabolic process in which cellular components, organelles, and misfolded proteins are degraded in lysosomes and recycled [1, 2] . Based on the mode of substrate delivery to lysosomes, autophagy is classified into three forms in most mammalian cells:
chaperone-mediated autophagy, microautophagy, and macroautophagy [3, 4] . Macroautophagy (hereafter referred to as autophagy) is believed to be the main pathway. This form of autophagy involves the delivery of cytoplasmic cargo sequestered inside double-membrane vesicles to the lysosome for degradation [2] . Autophagy is initiated by the formation of double-membrane vesicles, called autophagosomes, which sequester cellular components in a non-degradative compartment. Autophagosomes are then transported along microtubules to the perinuclear region (which contains the highest concentration of lysosomes)
where they fuse with lysosomes to form autolysosomes, in which the captured materials, together with the inner membrane, are degraded by lysosomal enzymes [2] .
Autophagy is responsible for the quality control of essential cellular components by clearance of damaged proteins and organelles. It can also be induced in cells under stress to aid in adjusting to changes in the environment [2, 5, 6] .
Autophagy plays a role in both health and disease.
Increasing evidence has implicated autophagic dysfunctions 
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Characteristics of Neuronal Autophagy
Scarcity of autophagosomes in healthy neurons
Autophagosomes are maintained at minimal numbers in healthy neurons. Previous studies using mice expressing green fluorescent protein-tagged microtubule-associated protein 1 light chain 3 (GFP-LC3) as an autophagosome marker showed that GFP-LC3-labeled autophagosomes do not occur in the brain, even after 48 h of food withdrawal [7] .
This was further confi rmed in another study which showed that normally cultured cortical neurons rarely contain [8] . An electron microscopic study of brain biopsy specimens also confirmed the scarcity of autophagosomes in healthy neurons [9] .
High efficiency of autophagosome clearance The scarcity of autophagic vacuoles (AVs) in healthy neurons initially led to the assumption that baseline autophagy in neurons is relatively inactive, but this now seems unlikely.
In fact, the processes of autophagosome formation, maturation, and digestion within lysosomes in normal neurons are constituently active and highly efficient. This has been highlighted by an insightful study which showed that blocking autophagosome clearance in cultured primary neurons by inhibiting lysosomal proteolysis causes rapid and marked AV accumulation without altering the induction of autophagy [8] .
Then, the question arose as to how to interpret the seemingly contradictory scenario in which neuronal autophagy is highly active but autophagosomes are rarely detected. To answer this conundrum, a key point is that the presence of autophagosomes depends on both their rates of production and clearance by lysosomes [10] .
Thus, the appearance of autophagosomes per se is not a measure of functional autophagy. Autophagic flux − the net rate of autophagosome content degradation through the autophagic pathway [11] − reflects the efficiency of the process. The efficient clearance of autophagosomes by basal autophagy accounts for the low levels of autophagosomes in healthy neurons.
Role of Basal Neuronal Autophagy
Essential (Atg5) and autophagy-related 7 (Atg7), specifically in the central nervous system, exhibit progressive neuronal degeneration and massive neuronal loss within the first few months of life [12, 13] . [14, 15] .
These studies provide strong evidence that continuous autophagy is normally responsible for clearing abnormal intracytoplasmic contents, which otherwise form protein aggregates, disrupt neuronal function, and ultimately lead to neurodegeneration.
Role of basal autophagy in the maintenance of axonal homeostasis Neurons are typically composed of a soma, a dendritic tree, and an axon. As a highly specialized neuronal compart ment, the axon performs many autonomous functions distant from the soma [16] . The fact that the axon transfers proteins and organelles via longdistance axoplasmic transport requires that the synthesis and anterograde transport of proteins and membrane be well-balanced by their clearance [17] . The products of endocytosis and autophagy are retrieved from axons by regulated retrograde organelle transport [17] . Accumulating evidence has revealed that, under normal conditions, autophagy is of particular importance for the maintenance of local axon homeostasis and protection against axonal degeneration [12, 13] .
Autophagy is uniquely regulated within the axonal compartment, independent of the dendrites and soma.
In earlier studies, Hollenbeck observed real-time autophagosome formation in the distal region of the axon, suggesting the local biogenesis of autophagosomes in axons [17] . Recent studies involving live imaging showed that autophagosomes are normally produced in the distal ends of axons and undergo retrograde transport to the soma for the completion of degradation [16, 18] .
Autophagy is required for normal axon terminal membrane trafficking and turnover. Aberrant membrane structures accumulate in axons when autophagy is suppressed in the mouse brain [19, 20] . In the abovementioned study by Hollenbeck, it was shown that the basal level of autophagy might be a key mechanism for remodeling neurite and growth-cone structure during neurite extension [17] . Autophagy might also work as an adaptive response to remodel axon terminal structures for regeneration after axonal injury [21] . Suppression of basal autophagy in the central nervous system causes neurodegeneration, accompanied by severe axonal swelling [12, 13] . Specific ablation of the essential autophagy gene Atg7 in Purkinje cells results in cell-autonomous axonal dystrophy and degeneration [19] , implying the indispensable role of autophagy in housekeeping functions in axon terminals and in protection against axonal degeneration.
Role of neuronal autophagy in synapse development
Synapses are regions of high energy-demand and proteinturnover; the morphological and functional modifications of synapses depend on coordinated protein synthesis and degradation [22] [23] [24] [25] [26] [27] . It is now clear that neuronal autophagy plays a crucial role in the development and remodeling of synapses, which is required for learning and memory [24, 25] .
Evidence shows that autophagy promotes synapse growth in the Drosophila neuromuscular junction by downregulating Highwire [28] . Overexpression of Atg1 is suffi cient to induce high levels of autophagy and subsequent enhancement of synaptic growth, while suppressing autophagy through mutations of genes essential for autophagy results in the reduction of synapse size. In Caenorhabditis. elegans, endocytosed gamma-amino butyric acid A receptors at inhibitory synapses are targeted to autophagosomes. By functioning as a degradative pathway for these receptors, autophagy serves as a mechanism to control the balance of neuronal excitation and inhibition [29] .
Neuropathological Evidence Linking Autophagic
Pathways to AD
Intraneuronal neurofibrillary tangles (NFTs) formed by aggregated hyperphosphorylated tau, and extracellular neuritic plaques mainly composed of aggregates of β-amyloid peptide (Aβ), are the neuropathological hallmarks of AD. As discussed above, abnormal autophagic proteolysis can lead to a build-up of waste proteins or unwanted aggregates. Electron microscopic studies of the AD brain by Nixon et al. showed that amyloid plaque-associated dystrophic neurites display a massive accumulation of AVs, providing the first pathological evidence for the extensive involvement of autophagy in the pathogenesis of AD [9] . Findings from the brains of PS1 M146L / APP 751SL mice that overexpress familial AD-related mutant human PS1 and APP genes suggest that the dystrophic neurites have excessive accumulation of AVs [30] . The abnormal accumulation of AVs has also been observed in several other animal models of AD, including APPswe/ PS1 M146L mice and TgCRND8 mice overexpressing mutant human APP695 [31, 32] . In contrast to the rarely-observed AVs in normal brains, the abundance of AVs in the brains of AD patients and AD animal models indicates that defective autophagic lysosomal proteolysis may underlie the pathogenic protein accumulation in AD.
Where Is the Autophagic Pathway Defective in AD?
The abnormal accumulation of autophagosomes in neurons constituted the fi rst clue of defi cits in autophagy. However, the precise mechanisms underlying autophagic dysfunction in AD are not fully understood. As described earlier in this review, the number of autophagosomes in a cell depends on the balance between AV formation and degradation.
The build-up of AVs in neurological disorders may reflect stimulation of the induction of autophagy, impairment of later digestive steps in the autophagic pathway, or a slow rate of autophagosome formation combined with insuffi cient lysosomal fusion and digestion [33] (Fig. 1) . Determining the defective step(s) along the autophagic pathway in AD is critical for understanding the pathogenic significance of autophagy in AD and developing potential therapeutic interventions based on the modulation of autophagy.
Altered Autophagy Initiation in AD
Evidence suggests that abnormalities of autophagy at the level of induction or autophagosome formation contribute to the pathogenesis of AD. Although autophagosomes are numerous in the AD brain and in the PS1 M146L / APP 751SL mouse model of AD, this does not necessarily mean that autophagy initiation is upregulated. In contrast, the expression of beclin-1, an essential initiator of autophagy, is decreased in AD patients compared with healthy individuals [34, 35] . Caspase 3-mediated cleavage of beclin-1 occurs in AD brains; the loss of beclin-1 is believed to be caused by the increased activity of this enzyme in AD patients [36] . The deletion of beclin-1 in an APP transgenic mouse model disrupts autophagy, and increases intracellular Aβ accumulation [34] . Conversely, a genome-wide research indicated that autophagy is 
Defective Lysosomal Clearance of Autophagic
Substrates in AD
The fi nal step of autophagy is the digestion of sequestered materials in autolysosomes. In addition to the defects in earlier stages of autophagy, accumulating evidence has suggested a critical role of lysosomal proteolytic failure in the development of AD-related neurodegeneration. The
AVs accumulating in the AD brain are electron-dense autolysosomes and autophagosomes filled with undigested or incompletely-digested "waste" proteins [9] . AV and lysosome fractions isolated from the brains of TgCRND8 mice contain abnormally high levels of LC3-II, ubiquitinated proteins, and Aβ [38] . The morphology of accumulated AVs in the AD brain and in the transgenic mouse model of AD resembles that induced by blocking lysosomal proteolysis by deleting specific cathepsins or administering lysosomal protease inhibitors [8, 39] . For example, selectively blocking cathepsin-mediated proteolysis within autolysosomes with cysteine-protease and aspartyl-protease inhibitors in neurons causes a marked accumulation of electron-dense double-membrane-limited AVs containing incompletely degraded LC3-II [8] . The above evidence strongly points to the disruption of substrate proteolysis within autolysosomes as the principal mechanism underlying autophagic dysfunction in AD. This possibility has been further underscored by the recent fi nding that presenilin 1 might be involved in the defective proteolysis of autophagic substrates in patients with AD. Presenilin 1 plays a critical role in lysosomal acidification and autophagosomelysosome fusion [40] [41] [42] . Fibroblasts from patients with familial substrate turnover in AD [40] .
Defective Autophagosome Transport
In normal neurites, immature AVs are transported retrogradely toward the soma for further degradation.
The significant build-up of AVs within dystrophic neurites in the AD brain suggests that their transport might be impeded. A selective transport deficit of autophagyrelated compartments has been reported in mouse and cell models of AD [43] . The possible role of defective axonal transport of AVs in AD pathogenesis is further suggested by the finding that inhibiting autophagosome delivery to lysosomes induces a rapid accumulation of AVs in neurites with morphology similar to that seen in the AD brain [8] .
Further studies are required to clarify the molecular defects underlying the transport failure of AVs.
To accurately identify and quantify the autophagic dysfunction in AD, specifi c protein markers and diagnostic methods are needed. Transmission electron microscopy is currently the "gold standard" for monitoring autophagy in tissue. Immunohistochemical staining and immunoblotting against autophagy-specific biomarkers such as LC3
have been widely used to assess autophagy [11] . Other approaches include the use of weakly basic dyes which accumulate in the acidic autophagosome-lysosome compartment, and forced expression of GFP-LC3 to detect AVs under the microscope as fl uorescent dots [11] . To date, there are no methods to monitor autophagy in vivo.
Exploring biomarkers that can be widely applied in clinical settings to assess the level of autophagy in AD is critical for improved understanding of the autophagic dysfunction in AD and for the successful development of therapies based on the modulation of autophagy.
Modulation of Autophagy as a Potential Therapy for AD
Since the initial observations that autophagic dysfunction may contribute to the accumulation of proteins in the AD brain, there has been a growing interest in manipulating autophagy as a potential therapeutic target for AD (Table 1) .
Therapeutic Induction of Autophagy
Pharmacological induction of autophagy has proved effective in reducing neuronal aggregates and slowing the progression of neurological symptoms in several mouse models of AD. The mammalian target of rapamycin (mTOR) is a critical negative regulator of autophagy [44] .
In the platelet-derived growth factor promoter expressing amyloid precursor protein transgenic AD mouse model, long-term inhibition of mTOR by rapamycin prevents ADlike cognitive defi cits and lowers the levels of Aβ42, a major toxic species in AD [46, 48] . As expected from the inhibition of mTOR, the induction of autophagy increases in the neurons of rapamycin-treated transgenic mice, suggesting that the reduction of Aβ is due in part to this increase [46] . In 3×Tg AD mice, inducing autophagy via rapamycin significantly reduces amyloid plaques, NFTs, and cognitive deficits [45] .
Induction of autophagy by administration of a lentiviral vector expressing beclin-1 reduces both intracellular and extracellular amyloid pathology in APP transgenic mice [34] . These findings and related studies [49] have led to the reasonable proposition that targeting the induction of autophagy can have potential therapeutic benefi ts in AD.
However, conflicting data from recent studies in AD models raise caution about the applicability of the induction of autophagy as a generalized treatment strategy for AD. For example, inhibition rather than stimulation of autophagy has been suggested to alleviate Aβ42-induced cell death [47, 50] .
Rapamycin treatment of flies expressing Aβ 1-42 results in a significantly shortened lifespan, indicating that enhancement of autophagy may enhance Aβ1-42 neurotoxicity [47] . Thus, it appears that although basal autophagy is required for neuronal survival, the benefi t of enhanced induction of autophagy is context-dependent.
The timing of intervention in the progression of the disease should be taken into account when implementing autophagy induction as a therapeutic approach. This is illustrated by the findings that increasing the induction of autophagy prior to the development of AD-like pathology in 3×Tg-AD mice reduces the levels of soluble Aβ and tau and amyloid plaques, whereas induction after the formation of mature plaques and tangles has no effect on AD-like pathology or cognitive deficits [45] . In addition, differences to a pathogenic condition [47] .
Then why would blocking autophagy be beneficial, given its protective role? The main reason is that enhanced autophagy does not necessarily lead to productive autophagy, i.e., an increase in autophagic fl ux. If the lysosomal clearance of autophagosomes is halted, the activation of autophagy results in the harmful accumulation of intermediate AVs.
Nixon and colleagues have shown that autophagosomes in AD brains may be a major reservoir of Aβ [51] . Enhancement of new autophagosome formation without a parallel increase in autophagic fl ux may actually increase Aβ production and leakage of the catabolic contents of AVs [52] .
Targeting Defective Lysosomal Proteolysis
The optimal modification of autophagic failure should enhance autophagosome clearance by the lysosome. substrates, and ameliorates amyloid pathologies and memory defi cits in the animals [38] . These fi ndings, together with other related studies [53] , suggest that restoring normal lysosomal proteolysis might be the key to developing novel therapeutic interventions against AD, although pharmacological compounds with such effects are not yet available. [44] .
PS1 M146V knock-in) 3×Tg-AD mice Food containing rapamycin Starting at 2 16 months Induction Reduced amyloid plaques, (2.24 mg/ kg) months of age NFTs and cognitive defi cits [45] . [45] .
PDAPP Tg mice Food containing rapamycin Starting at 4 13 weeks Induction Alleviated cognitive defi cits (hAPP(J20)) (2.24 mg/ kg) months of age and decreased soluble Aβ42 [46] . Aβ42-expressing fl ies Food containing 1 mmol/L NA NA Induction Shortened lifespan [47] .
rapamycin Aβ40-expressing fl ies Food containing 1 mmol/L NA NA Induction No changes in lifespan [47] . rapamycin Aβ42-expressing fl ies Neuron-specifi c Atg5RNAi NA NA Downregulation Increased lifespan [47] . expression Aβ40-expressing fl ies Neuron-specifi c Atg5RNAi NA NA Downregulation Shortened lifespan [47] .
expression TgCRND8 mice overGenetically deleting NA NA Enhanced lysosomal Reduced amyloid pathologies expressing mutant cystatin B proteolysis and memory defi cits [38] .
human APP695
PDAPP Tg mice Administration of a lentiviral NA NA Induction Reduced amyloid (hAPP(J20)) vector expressing beclin 1 pathology [34] .
Aβ, amyloid β; APP, amyloid precursor protein; Atg5, autophagy-related gene 5; NFTs, neurofi brillary tangles; PS1, presenilin 1; Tg, transgenic.
Combination Therapy
Successful greater efficiency in clearing protein aggregates [54, 55] .
Compared with either treatment alone, using two drugs in combination may enable reduction of the dose of each treatment, which might decrease the likelihood of adverse effects. 
Considerations for Therapeutic Use of Autophagy
Modulation in AD
Conclusion
Converging evidence has fi rmly established the importance of autophagic dysfunction in the pathogenesis of AD. A more complete understanding of the regulatory pathways of neuronal autophagy and further clarification of the pathogenic mechanisms of dysfunctional autophagy in AD will help the development of therapeutic interventions.
We also need new agents to target specific steps in the autophagic pathway to achieve more accurate modulation of autophagy. Future research should also make efforts
to address the precise determinants of the outcome of autophagic modulation.
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